Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Nano-biointeraction and nanopathology

Nano-biointeraction and nanopathology

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

New oncogene may contribute to high incidence of prostate cancer among African American men

New oncogene may contribute to high incidence of prostate cancer among African American men

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

Researchers awarded grant to develop safer cancer therapies for children

Researchers awarded grant to develop safer cancer therapies for children

Antibody drug offers new therapeutic approach for treating AML

Antibody drug offers new therapeutic approach for treating AML

Novel immunotherapy shows promise against AML in clinical trial

Novel immunotherapy shows promise against AML in clinical trial

HMS scientists reveal how certain tumors develop taste for fat

HMS scientists reveal how certain tumors develop taste for fat

Researchers uncover new molecular causes of brain cancer and leukemia

Researchers uncover new molecular causes of brain cancer and leukemia

Adolescent females have low rates of pregnancy screening prior to cancer treatment

Adolescent females have low rates of pregnancy screening prior to cancer treatment

New drug holds potential for treating advanced mastocytosis

New drug holds potential for treating advanced mastocytosis

Researchers find new way for early prediction of leukemic relapse

Researchers find new way for early prediction of leukemic relapse

Scientists identify new genetic variations contributing to onset of APL

Scientists identify new genetic variations contributing to onset of APL

TUM scientists discover molecular signaling pathway for self-destruction in leukemia cells

TUM scientists discover molecular signaling pathway for self-destruction in leukemia cells

JAX researchers find precise, reliable way to identify leukemia cells of origin

JAX researchers find precise, reliable way to identify leukemia cells of origin

Scientists identify set of genes that could predict clinical outcomes in patients with FLT3-ITD AML

Scientists identify set of genes that could predict clinical outcomes in patients with FLT3-ITD AML

Researchers demonstrate simple approach to prove how classes of new drugs work

Researchers demonstrate simple approach to prove how classes of new drugs work

Scientists discover new way to predict risk for delayed recovery in children with AML

Scientists discover new way to predict risk for delayed recovery in children with AML

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.